DOPHALINE
Board
2 directors, last change in 2023Director (not named in the articles)
appointed by deed of 27-12-2023
term without a fixed end
earlier manager, until 27-12-2023
listed in the 2026 annual accounts, filed on 06-10-2026
Director (not named in the articles)
appointed by deed of 27-12-2023
term without a fixed end
earlier manager, until 27-12-2023
listed in the 2026 annual accounts, filed on 06-10-2026
- Signing authorityThe articles say who may bind the company, for example by signing a contract.
- Each director alonedeed of 27-12-2023
Mandates through the years
2 names, the dashed line is todayDirector (not named in the articles)
Director (not named in the articles)
BoardEarliermandate already running before its first mention
Mandates as a list
-
- Director (not named in the articles), since before 31-03-2022
- Manager, until 27-12-2023
-
- Director (not named in the articles), since before 31-03-2022
- Manager, until 27-12-2023
Control
Parent
Equity €2.6m
Profit €6,868 in 2025 (profit €194,935 in 2024)
Checked score
Source: accounts 30-06-2025
99.52%
This company
DOPHALINE
Equity €3.9m
Profit €1.4m in 2026
Capital
- Contribution
- €105,000
- Source
- 2026 annual accounts
Owners through the years
as the annual accounts name themOwners as a list
-
- 2012 to 2025: 99.52%
Source: lists of holdings in the owners' accounts
Articles of association
deed of 27-12-2023 (in Dutch)- Transfer restrictionThis rule says whether shareholders may sell their shares freely or need approval first.
- “Overdracht van aandelen onder levenden, helft kandidaat-overdrager en helft overige aandeelhouders pro rata bezit inclusief erelonen en…”
- Financial yearThe company draws up its annual accounts over this twelve-month period.
- “ARTIKEL 26 - STEMRECHT - BERAADSLAGINGEN § 1. Op de algemene vergadering geeft ieder aandeel recht op één stem, onder voorbehoud van de…”
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- First Saturday of September at 14:00
Capital transactions
Capital over time
- 27-12-2023 Converted to unavailable equity · €115,500
- 27-12-2023 Converted to available equity · €115,500